Analysis of NRG trial in limited-stage small cell lung cancer suggests QOL benefit with twice- vs. once-daily radiation

Previously, the primary endpoint results of the NRG-LU005 study assessing the addition of the immunotherapy drug atezolizumab to standard of care concurrent chemoradiation for limited-state small cell lung cancer were reported at the American Society for Radiation Oncology 2024 Annual Meeting.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup